Skye Bioscience (SKYE) Non-Current Debt (2013 - 2023)
Skye Bioscience (SKYE) posted quarterly Non-Current Debt of $4.4 million for Q4 2023, up 136.53% year-over-year from $1.8 million in Q4 2022, and up 136.53% quarter-over-quarter from $1.8 million in Q4 2022.
Skye Bioscience (SKYE) Non-Current Debt (2013 - 2023) Analysis & Trends
Skye Bioscience (SKYE) has reported Non-Current Debt for 5 consecutive years, with $4.4 million the latest figure, recorded in Q4 2023.
- In Q4 2023, Non-Current Debt rose 136.53% year-over-year to $4.4 million; the TTM figure through Dec 2023 stood at $4.4 million (up 136.53% YoY), while the FY2023 annual figure was $4.4 million, up 136.53% from the prior year.
- Non-Current Debt improved to $4.4 million in Q4 2023 per SKYE's latest filing, from $1.8 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $4.4 million in Q4 2023 and bottomed at $13177.0 in Q1 2021.
- Historically, Non-Current Debt has averaged $995589.0 across 4 years, with a median of $450000.0 in 2021.
- On a YoY basis, Non-Current Debt climbed as much as 12647.52% in 2022 and fell as far as 0.0% in 2022.
- Skye Bioscience's Non-Current Debt stood at $52638.0 in 2020, then jumped by 2796.97% to $1.5 million in 2021, then grew by 21.21% to $1.8 million in 2022, then soared by 136.53% to $4.4 million in 2023.
- Business Quant data shows SKYE's Non-Current Debt at $4.4 million in Q4 2023, $1.8 million in Q4 2022, and $450000.0 in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.70 Bn | 131.85 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.75 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 65.36 Bn | 60.18 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.15 Bn | 54.01 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.88 Bn | 28.57 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | 8.96 Bn |
| 10 | Skye Bioscience | 10.56 Mn | 10.56 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 4.37 Mn |
| Dec 31, 2022 | 1.85 Mn |
| Sep 30, 2022 | 450,000.00 |
| Jun 30, 2022 | 450,000.00 |
| Mar 31, 2022 | 1.68 Mn |
| Dec 31, 2021 | 1.52 Mn |
| Sep 30, 2021 | 450,000.00 |
| Mar 31, 2021 | 13,177.00 |
| Dec 31, 2020 | 52,638.00 |
| Sep 30, 2020 | 45,598.00 |
| Jun 30, 2020 | 65,047.00 |
| Apr 30, 2013 | 15,851.00 |